📣 VC round data is live. Check it out!
- Public Comps
- Danaher
Danaher Valuation Multiples
Discover revenue and EBITDA valuation multiples for Danaher and similar public comparables like Stryker, Medtronic, Abbott, Intuitive Surgical and more.
Danaher Overview
About Danaher
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
Founded
1986
HQ

Employees
60.0K
Website
Financials (LTM)
EV
$127B
Valuation Multiples
Start free trialDanaher Financials
Danaher reported last 12-month revenue of $25B and EBITDA of $8B.
In the same LTM period, Danaher generated $15B in gross profit, $8B in EBITDA, and $6B in net income.
Revenue (LTM)
Danaher P&L
In the most recent fiscal year, Danaher reported revenue of $25B and EBITDA of $8B.
Danaher is profitable as of last fiscal year, with gross margin of 59%, EBITDA margin of 31%, and net margin of 23%.
Financial data powered by Morningstar, Inc.
Danaher Stock Performance
Danaher has current market cap of $115B, and enterprise value of $127B.
Market Cap Evolution
Danaher's stock price is $161.91.
Danaher share price decreased by 9.5% in the last 30 days, and by 14.7% in the last year.
Danaher has an EPS (earnings per share) of $7.89.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $127B | $115B | 0.0% | -9.5% | -23.1% | -14.7% | $7.89 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDanaher Valuation Multiples
Danaher trades at 5.1x EV/Revenue multiple, and 16.2x EV/EBITDA.
EV / Revenue (LTM)
Danaher Financial Valuation Multiples
As of May 17, 2026, Danaher has market cap of $115B and EV of $127B.
Danaher has a P/E ratio of 19.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Danaher Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Danaher Margins & Growth Rates
Danaher grew revenue by 4% and EBITDA by 6% in the last fiscal year.
In the most recent fiscal year, Danaher reported gross margin of 59%, EBITDA margin of 31%, and net margin of 23%.
Danaher Margins
Danaher Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Danaher Operational KPIs
Danaher's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Danaher's Rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Danaher's Rule of X is 41% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Danaher Competitors
Danaher competitors include Stryker, Medtronic, Abbott, Intuitive Surgical, Boston Scientific, Thermo Fisher Scientific, Hoya, Edwards Lifesciences, Wuxi AppTec and Siemens Healthineers.
Most Danaher public comparables operate across Medical Devices, Laboratory Services, Medical Supplies, BioTech, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 5.2x | 5.0x | 18.0x | 17.5x | |||
| 3.5x | 3.2x | 12.1x | 11.5x | |||
| 3.9x | 3.7x | 14.4x | 14.1x | |||
| 14.4x | 13.5x | 33.2x | 30.8x | |||
| 4.4x | 4.2x | 14.1x | 13.6x | |||
| 4.6x | 4.4x | 17.6x | 17.6x | |||
| 10.0x | 9.1x | 28.5x | 24.0x | |||
| 7.2x | 6.9x | 24.2x | 22.8x | |||
This data is available for Pro users. Sign up to see all Danaher competitors and their valuation data. Start Free Trial | ||||||
Danaher M&A Activity
Danaher has acquired 17 companies to date.
Last acquisition by Danaher was on February 17th 2026. Danaher acquired Masimo for $10B (EV/Revenue multiple of ).
Latest Acquisitions by Danaher
| Description | Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies. | Genedata is a Basel-headquartered provider of computational software platforms for biopharmaceutical research and development. The company offers Genedata Screener for high-throughput screening data analysis, Genedata Biologics for therapeutic antibody discovery and engineering, and Genedata Profiler for biomarker data management. These platforms handle petabyte-scale datasets from genomes, transcriptomes, proteomes, and metabolomes. Founded in 1997, Genedata serves more than 300 organizations worldwide, including Novartis, Roche, and Pfizer, across 40 countries. Its solutions integrate with major instrument vendors and support regulatory compliance in discovery workflows from target identification to clinical development. | Abcam is a life sciences supplier of research-grade antibodies, assays, and reagents for applications in cancer, neuroscience, infectious diseases, and immunology. Headquartered in Cambridge, UK, with facilities in the United States, Europe, and Asia, Abcam serves over 100,000 academic and pharma labs with products validated for Western blot, IHC, and flow cytometry. | Aldevron is a Fargo-headquartered contract development and manufacturing organization specializing in plasmid DNA, mRNA, and viral vector production. Founded in 1998, it operates GMP facilities producing 100+ kilograms of plasmid annually for gene therapy and vaccines. Acquired by Danaher in 2021 for $1.6 billion, Aldevron supplies clients like Moderna and supports 500+ programs worldwide. Its Fargo campus spans 200,000 square feet. | |
| HQ Country | |||||
| HQ City | Los Angeles, CA | Basel | — | Fargo, ND | |
| Deal Date | 17 Feb 2026 | 19 Aug 2024 | 28 Aug 2023 | 17 Jun 2021 | |
| Valuation | $10B | undisclosed | $6B | $10B | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Danaher acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Danaher
| When was Danaher founded? | Danaher was founded in 1986. |
| Where is Danaher headquartered? | Danaher is headquartered in United States. |
| How many employees does Danaher have? | As of today, Danaher has over 60K employees. |
| Who is the CEO of Danaher? | Danaher's CEO is Rainer M. Blair. |
| Is Danaher publicly listed? | Yes, Danaher is a public company listed on NYSE. |
| What is the stock symbol of Danaher? | Danaher trades under DHR ticker. |
| When did Danaher go public? | Danaher went public in 1978. |
| Who are competitors of Danaher? | Danaher main competitors include Stryker, Medtronic, Abbott, Intuitive Surgical, Boston Scientific, Thermo Fisher Scientific, Hoya, Edwards Lifesciences, Wuxi AppTec, Siemens Healthineers. |
| What is the current market cap of Danaher? | Danaher's current market cap is $115B. |
| What is the current revenue of Danaher? | Danaher's last 12 months revenue is $25B. |
| What is the current revenue growth of Danaher? | Danaher revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Danaher? | Current revenue multiple of Danaher is 5.1x. |
| Is Danaher profitable? | Yes, Danaher is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Danaher? | Danaher's last 12 months EBITDA is $8B. |
| What is Danaher's EBITDA margin? | Danaher's last 12 months EBITDA margin is 32%. |
| What is the current EV/EBITDA multiple of Danaher? | Current EBITDA multiple of Danaher is 16.2x. |
| What is the current FCF of Danaher? | Danaher's last 12 months FCF is $5B. |
| What is Danaher's FCF margin? | Danaher's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of Danaher? | Current FCF multiple of Danaher is 23.6x. |
| How many companies Danaher has acquired to date? | As of May 2026, Danaher has acquired 17 companies. |
| What was the largest acquisition by Danaher? | $21B acquisition of Cytiva on 31st March 2020 was the largest M&A Danaher has done to date. |
| What companies Danaher acquired? | Danaher acquired Cytiva, Pall, Masimo, Aldevron, Abcam, Cepheid, Nobel Biocare, Integrated DNA Technologies, Phenomenex, Advanced Vision Technology, and 7 other companies. |
| In how many companies Danaher has invested to date? | Danaher hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Danaher
Lists including Danaher
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


